Sugi Predict

Sugi Predict / Compounds / SCHEMBL20547722

SCHEMBL20547722

SCHEMBL20547722

N#Cc1ccc(C(=O)CCC(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.59
▸ MAPT P10636 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ NLRP3 Q96P20 1/20 0.54
▸ CA1 P00915 2/20 0.50
▸ CA2 P00918 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ MMP1 P03956 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28755880 0.85 GSK3B (0.49) GSK3BMAPTLMNATSHRHTT
SCHEMBL16552727 0.84 GSK3B (0.70) GSK3BMAPTLMNATSHRCA1
SCHEMBL29043250 0.83 GSK3B (0.46) GSK3BMAPTLMNATSHRHTT
SCHEMBL5737219 0.83 MMP2 (0.62) GSK3BLMNACA1CA2KMT2A
SCHEMBL9694596 0.82 TSHR (0.59) GSK3BMAPTLMNATSHRHTT
SCHEMBL6320432 0.82 MAPT (0.54) GSK3BMAPTLMNATSHRHTT
SCHEMBL21774365 0.81 GSK3B (0.59) GSK3BMAPTCA1CA2MEN1
SCHEMBL20547701 0.81 GSK3B (0.65) GSK3BCA1CA2MEN1KMT2A
SCHEMBL1535173 0.80 MAOA (0.56) GSK3BMAPTLMNATSHRHTT
SCHEMBL29637479 0.80 GSK3B (0.40) GSK3BMAPTLMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637424-B2 Pharmaceutical salt of an arylpyrrole derivative SENTINEL ONCOLOGY LIMITED (GB) 2026-05-26 — — US disclosed
CN-114585605-B Pharmaceutical compounds 圣提内尔肿瘤学有限公司 2025-02-25 — — CN disclosed
EP-3615525-B1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS SENTINEL ONCOLOGY LTD (GB) 2024-12-25 — — EP disclosed
US-20240140908-A1 A PHARMACEUTICAL SALT OF AN ARYLPYRROLE DERIVATIVE SENTINEL ONCOLOGY LIMITED (GB) 2024-05-02 — — US disclosed
US-11884656-B2 Pyrrole derivatives as PLK1 inhibitors SENTINEL ONCOLOGY LIMITED (GB) 2024-01-30 — — US disclosed
EP-4217343-A1 A PHARMACEUTICAL SALT OF AN ARYLPYRROLE DERIVATIVE Sentinel Oncology Limited (GB) 2023-08-02 — — EP disclosed
CN-116348105-A Pharmaceutically acceptable salts of arylpyrrole derivatives 圣提内尔肿瘤学有限公司 2023-06-27 — — CN disclosed
US-20220348565-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2022-11-03 — — US disclosed
WO-2022063899-A9 A PHARMACEUTICAL SALT OF AN ARYLPYRROLE DERIVATIVE SENTINEL ONCOLOGY LIMITED (GB) 2022-09-22 — — WO disclosed
EP-4034246-A1 PHARMACEUTICAL COMPOUNDS Sentinel Oncology Limited (GB) 2022-08-03 — — EP disclosed
US-20220135552-A1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2022-05-05 — — US disclosed
WO-2022063899-A1 A PHARMACEUTICAL SALT OF AN ARYLPYRROLE DERIVATIVE SENTINEL ONCOLOGY LIMITED (GB) 2022-03-31 — — WO disclosed
US-11208405-B2 Pyrrole derivatives as PLK1 inhibitors SENTINEL ONCOLOGY LIMITED (GB) 2021-12-28 — — US disclosed
US-11208405-B2 Pyrrole derivatives as PLK1 inhibitors SENTINEL ONCOLOGY LIMITED (GB) 2021-12-28 — — US disclosed
WO-2021058754-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2021-04-01 — — WO disclosed
WO-2021058754-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2021-04-01 — — WO disclosed
US-20200247796-A1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2020-08-06 — — US disclosed
US-20200247796-A1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2020-08-06 — — US disclosed
EP-3615525-A1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS Sentinel Oncology Limited (GB) 2020-03-04 — — EP disclosed
WO-2018197714-A1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2018-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637424-B2 Pharmaceutical salt of an arylpyrrole derivative SLC10A2, CLIC1, SLC10A1 GSK3B 2065/4885MAPT 528/4885LMNA 4597/4885
US-20220348565-A1 PHARMACEUTICAL COMPOUNDS PLK1, PLK4, PLK2 GSK3B 11/4885MAPT 263/4885LMNA 2504/4885
US-11884656-B2 Pyrrole derivatives as PLK1 inhibitors PLK1, CDK1, AURKC GSK3B 274/4885MAPT 1171/4885LMNA 2048/4885
US-20200247796-A1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS PLK1, CDK1, AURKC GSK3B 278/4885MAPT 1193/4885LMNA 2046/4885
US-20240140908-A1 A PHARMACEUTICAL SALT OF AN ARYLPYRROLE DERIVATIVE DNPEP, JAK2, PTPRS GSK3B 2580/4885MAPT 1238/4885LMNA 4675/4885
US-20220135552-A1 PYRROLE DERIVATIVES AS PLK1 INHIBITORS PLK1, CDK1, AURKC GSK3B 274/4885MAPT 1171/4885LMNA 2048/4885
US-11208405-B2 Pyrrole derivatives as PLK1 inhibitors PLK1, CDK1, AURKC GSK3B 278/4885MAPT 1193/4885LMNA 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.